Amiodarone to reduce post-cardiopulmonary bypass systemic inflammatory response

Medical University of Vienna, Department of Cardiology (Austria)0 个研究点目标入组 40 人开始时间: 2005年11月15日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•Patients older than 40 years and younger than 75 years old undergoing non-emergent coronary-artery bypass surgery (CABG) with CPB were eligible for the study

•1. A history of adverse events to AMIO
•2. Concurrent treatment with AMIO within four months of enrolment
•3. The use of antiarrhythmic therapy other than beta-receptor blockers
•4. Calcium channel blockers or digitalis
•5. A C-reactive protein (CRP) concentration above normal (>0.5 mg/dl)
•6. A serum asparate aminotransferase or an alanine aminotransferase concentration four times the upper limit
•7. Child bearing potential
•8. An untreated thyroid dysfunction (thyroid-stimulating hormone [TSH] <0.01, >10 miU/ml)
•9. Chronic renal failure (serum creatinine >114 µmol/l)
•10. An ejection fraction <30% (determined either by nuclear, left flourescence ventriculography or echocardiography)
•11. Diabetes mellitus
•12. Unstable angina
•13. A resting heart rate of less than 50 beats per minute
•14. An active infection
•15. Malignancy
•16. Chronic atrial fibrillation

发起方

Medical University of Vienna, Department of Cardiology (Austria)